Day 1 – Wednesday, September 13
09:00 LSX Welcome Address
Jade Osei-Tutu, Sr. Conference Director, LSX
09:10 Keynote Panel: Is Data Pharma's Next Blockbuster? Big Pharma’s Global Digital Health Priorities and Strategy
Having made their way from the basement to the executive suite, technologies like artificial intelligence (AI) and machine learning are now shaping the future of the life sciences industry – and data is the foundation that drives these technologies forward. However, without the right tools to help manage and process it, the best data in the world can quickly become useless. Embracing data is a crucial step on the journey to building a digitally transformed company and evolving your technology strategy across the entire life sciences lifecycle. Solutions to good data management can help save pharmaceutical companies billions of dollars and significantly improve the time it takes to bring life-saving new drugs to market, but the industry is still fraught with questions when it comes to centralizing, standardizing, and managing data – then transforming that data into action. Four leaders in life science’s data transformation will discuss those questions, addressing the challenges and opportunities that come with employing data to effectively deliver on a patient-centric mission.
9:50 Keynote Panel: Achieving Scale and Profitability in Healthtech Businesses
10:30 Morning Break
11:00 Overcoming the Challenges of Developing Digital Health Products-A Pharma Perspective
11:40 Designing for Impact - Digital Health Products that Drive Engagement
The user experience of your digital health product is key to creating sustained engagement and a positive impact on people’s health. No matter how advanced your treatment or technology is, if the product is not designed to be engaging, accessible, user-friendly and to look trustworthy, people simply won’t use it. Thomas Michalak sets out to dispel the myth of “build it and they will come” in digital health, exploring how digital habits are formed and behaviours are changed, and how strong design builds trust and drives repeat engagement.
Thomas Michalak, Creative Director, Graphite Digital
12:00 How are New Digital Innovations Revolutionising Clinical Trials?
The era of clinical trials as we known them is coming to an end. The rising costs of running a trial, coupled with the commercial risks of failure, are unsustainable. This disruptive state is driving the adoption of new technologies and catalysing the digital transformation of clinical trials.
12:45 Lunch Break
13:45 Driving Greater Adoption of Digital Therapeutics into Healthcare Systems
This discussion will focus on what happens once effective DTx is solution built and clinically validated, how do we get it into the hands of those that need it the most? Hear the lessons learned from healthcare leaders on the forefront of the digital therapeutics’ revolution.
14:40 Creating Successful Digital Health-Pharma Partnerships and Collaborations
15:30 Afternoon Break
16:00 Revolutionizing Healthcare - Exploring New Applications of AI/ML
How are we using data technology and advanced analytics (artificial intelligence, machine learning, and deep learning) to advance our understanding of disease and deliver breakthroughs that change patients' lives?
Moderator: Geof Hannigan, Executive Director & Co-Founder, Merck Digital Sciences Studio
Neil Sahota, United Nations Artificial Intelligence Advisor & CEO, ACSILabs
Daniel-Adriano Silva, CEO & Co-Founder, Monod
Lana Feng, Founder & CEO, Huma.AI
Stacie Calad-Thomson, Chief Strategy Officer & Head of Drug Discovery, BioSymetrics
16:40 Fireside Chat: Driving Growth, Innovation, and Investment in Women’s Health
Discussing the dynamics in the Women’s Health space, drivers in the market, the vision for the growth of technology innovations in women’s health, and how do we as a sector plan to empower women globally?
17:00 Panel: Playing the Long Game-Healthtech Investment, Deals and Dollars
Due to the complexities within health technology and the health system’s complex regulation, it can be argued that a truly long-term approach is required from partners and investors. Despite the dip in digital health funding in 2022, the potential for long-term success in the healthtech space remains very real with the right strategies in place. This session will discuss the growth in partnerships with venture capital firms, the changing funding environment, and what healthtech investment activity in 2023 looks like so far.
17:40 Drinks Reception
Day 2 – Thursday, September 14
09:00 LSX Welcome Address
Jade Osei-Tutu, Sr. Conference Director, LSX
09:10 Keynote Presentation: Remote Monitoring and the Future of Connected Care
The pandemic underscored the need for connected healthcare, especially for patients who needed to be monitored closely in lower acuity areas of care in the hospital and at home after hospital discharge. There is a continued, growing need and market for remote care, particularly for patients who are transitioning from higher to lower acuity settings and home. The current Medtronic Patient Monitoring business, with a portfolio of hundreds of products and $1.4B in annual revenue, is helping drive development of innovative solutions that improve patient outcomes, reduce healthcare costs, and expand patient access to care–both in and out of the hospital. With the help of advanced technology, remote patient monitoring technologies aim to support patients where they have typically not been well-monitored in low acuity areas of care in the hospital and after they are discharged from the hospital, while also alerting providers to potentially critical changes in their patients' health.
James Mault, CEO, BioIntelliSense
09:30 Making Sense Of Device Data: Helping Clinicians Take Action With Their Patients
The sophistication of today's patient monitoring technologies has allowed healthcare providers to gain new insights into a patient's condition. While this information has been a game-changer in patient care, the burden of multiple datasets from different sources can cause confusion and can overwhelm providers. How can device makers and digital health companies leverage the power of electronic health records (EHRs) (interconnectivity) and AI to make sense of this information and make it more actionable for clinicians?
10:20 Morning Break
11:00 Value-Based Care and the Future of Health
11:50 Moving Mental Health into the Mainstream-Scaling Behavioural Healthtech
12:40 Lunch Break
14:00 Unlocking the Potential of Real-World Evidence and Real-World Data in Healthcare
14:40 Best Practice when Launching and Running a Digital Therapeutic Clinical Trial
15:20 The CVC Playbook-Where are CVCs Placing their Bets?
16:00 Close of Congress
Company Showcases
Day 1 – Wednesday, September 13
Day 2–Thursday, September 14th- 11:00
11:00 Welcome Introductions
11:05 Equitable AI: Generating Inclusive AI Healthcare Models
The rapid growth of AI tools in healthcare offers both opportunities and challenges for diversity and equity. To ensure inclusivity, companies are addressing diversity and bias in their models, and government agencies are seeking public input to eliminate bias. Principles and guidelines are being developed to prioritize equity without stifling innovation, and patient privacy is carefully considered. Training AI models at a granular level account for cultural, social, and clinical differences among populations, fostering equitable AI in healthcare while promoting progress.
Wendy Chow, Of Counsel, Morrison Foerster
11:25 HealthTech's Multifurcation Challenge: Accurately Representing Diverse Population Segments and Building Heterogeneous Data from Homogeneous Areas
This discussion tackles how companies can accurately represent diverse population segments with ongoing privacy concerns, biases, and data silos. With the building of heterogeneous data from homogenous areas hindering inclusive AI models, overcoming these hurdles demands collaboration, innovative data collection, and ethical considerations for equitable healthcare advancements.
Neil Sahota, CEO, ACSILabs
11:45 Why AI Ventures Are Bucking Investment Trends?
Despite the decline in global venture funding in early 2023, AI remains an appealing investment opportunity. From the perspective of an investor, will this interest remain, and how can healthtech companies access this rush in funding?
Martin Gershon, Managing Partner & CIO, Endeavor Venture Fund
Gary Stewart, Managing Director, Techstars
12:05 General Discussion & Closing Remarks
12:15 End of Forum
.png?width=300&height=79&name=LSX%20Pharma%20Digital%20Leaders%20Forum%20(new).png)
Day 1–Wednesday, September 13th - 16:00
Exclusively for CDOs/CTOs/Global Heads of Digital/Digital Health/Digital Transformation and at top 50 Big Pharma companies, the Pharma Digital Leaders Forum is the regular meeting place for those driving the digitisation at the world's largest pharma companies.
The Forum is intimate, exclusive and attendance is by invitation-only.
Co-hosted by:
16:00 Welcome Introductions
16:10 Evaluating the Digital Shift in the Pharma Sector
Digital transformation continues to be a critical strategic imperative for the pharma industry. As companies continue to build and mature digital capabilities there is an increasing importance placed on business value, impact and ROI. Given this and the current economic and environmental factors, pharma companies are now faced with choices about where to focus their digital efforts and how much effort to place on execution vs innovation. Clearly there needs to be a portfolio of initiatives that address both, but where is the greatest potential for value? During this session, we will explore the notion of whether companies should be more execution or innovation focused and why. Specifically, we will discuss the following types of questions:
Jonathan Fox, Digital Strategy & Innovation, Deloitte
16:40 Where Is The Digital Health Ecosystem Headed?
Hassan Naqvi, Head of Digital Health Partnerships, AstraZeneca
16:55 Leveraging AI & Machine Learning: Raising Confidence in Public Health and Improving Health Outcomes
Marcy Rudowitz, Associate Director, Global Voice of Customer Program, Moderna
17:10 General Discussion & Summary of Roundtable
17:30 End of Forum
Day 2- Thursday, September 14th - 11:00am
LSX’s IPO Workshop offers executives the chance to exchange ideas with and seek advice from experts in an interactive group setting. They are an opportunity to unpack key processes, procedures and KSFs to a successful listing and considerations for other routes public.
IPO Workshop: “3 Ps” of Going Public – Preparation, Path, and Post Transaction
For companies, founders, and entrepreneurs considering entrance into the public markets, this session will focus on the “3 Ps” of going public – preparation, path, and post-transaction; and the different ways to go public in challenging markets. Are you and your board prepared? What path is most appropriate for you: traditional or an alternative ‘going public avenue. How can you best prepare for success post-transaction?
John Rudy, Member, Mintz
Co-hosted by:
Day 2- Thursday, September 14th - 2:00pm
LSX’s IP Workshop offers executives the chance to hear from experts and get the right advice and best practice from experts on the critical consideration of IP. The workshop will provide a guide to intellectual property in life sciences and robustly protecting innovation.
Essential Guide to Intellectual Property in Life Sciences Transactions and Protecting Medicines
Chad E. Davis, Ph.D., Partner, Dechert
Hosted by:
.png?width=150&height=84&name=Mediloom%20(1).png)
